Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

New CEOs for Catalyst, FibroGen, Pheon and Tae

Plus: Nicole Sweeny named chief commercial officer of KalVista 

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst  
July 26, 2023 12:06 AM UTC

Catalyst Biosciences Inc. (NASDAQ:CBIO) co-founder Patrick McEnany plans to retire as CEO by year-end while remaining chairman. The rare disease company has initiated a search for a successor. 

 Enrique Conterno resigned as CEO of FibroGen Inc. (NASDAQ:FGEN) for personal reasons. Chief Commercial Officer Thane Wettig has been named interim CEO...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Catalyst Biosciences Inc.

Fibrogen Inc.

Kalvista Pharmaceuticals Inc.

Pheon Therapeutics Ltd.